

# Sabine Heitzeneder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1806512/publications.pdf>

Version: 2024-02-01

25  
papers

1,852  
citations

840776

11  
h-index

996975

15  
g-index

26  
all docs

26  
docs citations

26  
times ranked

2979  
citing authors

#	ARTICLE	IF	CITATIONS
1	GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. <i>Cancer Cell</i> , 2022, 40, 53-69.e9.	16.8	60
2	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. <i>Nature Medicine</i> , 2022, 28, 333-344.	30.7	105
3	Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. <i>Cell</i> , 2022, 185, 1745-1763.e22.	28.9	88
4	Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. <i>Science</i> , 2021, 372, .	12.6	297
5	Abstract 1548: Potent activity of CAR T cells targeting the oncofetal protein GPC2 engineered to recognize low antigen density in neuroblastoma. , 2021, , .		0
6	Tuning the Antigen Density Requirement for CAR T-cell Activity. <i>Cancer Discovery</i> , 2020, 10, 702-723.	9.4	296
7	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. <i>Nature Medicine</i> , 2020, 26, 712-719.	30.7	172
8	Abstract PR04: Locoregionally administered B7H3-targeting CAR T cells mediate potent antitumor effects in atypical teratoid/rhabdoid tumor. , 2020, , .		1
9	Abstract PR07: GD2 is a macrophage checkpoint molecule and combined GD2/CD47 blockade results in synergistic effects and tumor clearance in xenograft models of neuroblastoma and osteosarcoma. <i>Cancer Research</i> , 2020, 80, PR07-PR07.	0.9	4
10	Abstract A09: Glypican-2 targeted CAR T cells designed to effectively eradicate endogenous site density solid tumors in the absence of toxicity. , 2020, , .		0
11	Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. <i>Journal of the National Cancer Institute</i> , 2019, 111, 970-982.	6.3	43
12	IMMU-09. LOCALLY ADMINISTERED CAR T CELLS DEMONSTRATE MOST FAVORABLE ROUTE OF ADMINISTRATION IN A MODEL OF ATRT. <i>Neuro-Oncology</i> , 2019, 21, ii94-ii95.	1.2	1
13	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2560-2574.	7.0	369
14	ATRT-25. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON ATYPICAL RHABDOID TERATOID TUMOR (ATRT) AND IS A PROMISING CANDIDATE FOR CAR T CELL THERAPY. <i>Neuro-Oncology</i> , 2018, 20, i33-i33.	1.2	0
15	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. <i>Cancer Cell</i> , 2017, 31, 476-485.	16.8	116
16	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. <i>Cancer Cell</i> , 2017, 32, 295-309.e12.	16.8	148
17	327 B7-H3 Chimeric Antigen Receptor Modified T Cells Show Potent Anti-Tumor Activity in a Preclinical Model of Glioblastoma. <i>Neurosurgery</i> , 2017, 64, 272.	1.1	0
18	IMMU-45. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON MEDULLOBLASTOMA AND PROVES TO BE A PROMISING CANDIDATE FOR CAR T CELL IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2017, 19, vi122-vi122.	1.2	0

#	ARTICLE	IF	CITATIONS
19	IMMU-07. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON MEDULLOBLASTOMA AND PROVES TO BE A PROMISING CANDIDATE FOR CAR T CELL IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2017, 19, iv28-iv29.	1.2	3
20	Abstract 1597: Inhibition of the novel therapeutic target pregnancy associated plasma protein A (PAPP-A) in Ewing sarcoma enhances efficacy of IGF1R targeting in vivo. , 2017, , .		0
21	Abstract 685: GPC2 is an oncogene and immunotherapeutic target in high-risk neuroblastoma. , 2017, , .		0
22	Abstract 571: Pregnancy associated plasma protein A (PAPP-A) is a potential novel therapeutic target in Ewing sarcoma. , 2016, , .		0
23	Mannan-binding lectin deficiency attenuates acute GvHD in pediatric hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1127-1129.	2.4	3
24	Abstract 1357: Preferential expression of CD99 isoform variant 5 (CD99v005) in Ewing sarcoma compared to normal tissues. , 2015, , .		0
25	Mannan-binding lectin deficiency " Good news, bad news, doesn't matter?. <i>Clinical Immunology</i> , 2012, 143, 22-38.	3.2	146